Silence Therapeutics (LON:SLN) posted its quarterly earnings results on Tuesday, March 6th. The company reported GBX (2.30) (($0.03)) earnings per share for the quarter, Bloomberg Earnings reports. The business had revenue of GBX 2 million during the quarter. Silence Therapeutics had a negative net margin of 34,475.00% and a negative return on equity of 21.42%.
Silence Therapeutics (SLN) traded up GBX 6 ($0.08) during trading hours on Wednesday, hitting GBX 202 ($2.79). The company had a trading volume of 2,500 shares, compared to its average volume of 14,222. Silence Therapeutics has a fifty-two week low of GBX 71.88 ($0.99) and a fifty-two week high of GBX 254.75 ($3.52). The firm has a market capitalization of $137.24 and a PE ratio of -10,100.00.
Separately, Peel Hunt initiated coverage on Silence Therapeutics in a research report on Thursday, December 14th. They set a “buy” rating and a GBX 276 ($3.81) price target for the company.
Silence Therapeutics Company Profile
Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.